Share this article
LAS VEGAS, March 11, 2021 /PRNewswire/ DelveInsight s
Treatment-Resistant Depression (TRD) Market report provides a thorough comprehension of the Treatment-Resistant Depression, historical and forecasted epidemiology, and the TRD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the
The FDA approved
SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
In March 2019, the FDA approved
Global Psilocybin Market & Emerging Insights Report 2020-2030: Product Detail, Mechanism of Action, Dosage and Administration, & Research and Development Activity
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Treatment-Resistance Depression Treatment Making Advances: Study
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
FactMR: Treatment-Resistance Depression Treatment Making Advances: Study
Initiatives undertaken to spread awareness on mental health will fuel demand for treatment-resistance depression treatment
NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Market research firm Fact.MR ongoing study presents bullish outlook on the treatment-resistance depression treatment market. As per the World Health Organization s (WHO s) factsheet, more than 264 million people worldwide of various age groups suffer from depression. Coupled with this, the prevalence of treatment-resistant depression is peaking, especially in America and several countries across Europe.
Treatment-resistant depression (TRD) continues to be one of the highly neglected public health issue. A BMC Psychiatry study has found that treatment resistance is common among patients identified with major depressive disorders. Against this backdrop, the demand for treatment-resistance depression treatment is poised to surge.